Von Hippel Lindau Antibody

This product is produced by and distributed for Abnova, a company based in Taiwan.

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Images	Ratings	Applications	Species	Date	Details
Enlarge	5 reviewed by: Helder Andre	IF	Human	05/14/2015	View Summary Application Immunofluorescence Sample Tested ARPE-19 cells Species Human

Array H00007428-D01P

• Von Hippel Lindau Antibodies
• Von Hippel Lindau ELISA Kits
• Von Hippel Lindau Lysate
• Von Hippel Lindau Protein